Aligos Therapeutics (ALGS) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

ALGS Stock Forecast


Aligos Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a -68.59% downside from ALGS’s last price of $9.55) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.

ALGS Price Target


The average price target for Aligos Therapeutics (ALGS) is $3.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential -68.59% downside from ALGS's last price of $9.55.

ALGS Analyst Ratings


Hold

According to 13 Wall Street analysts, Aligos Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for ALGS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (30.77%), 8 'Hold' (61.54%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).

Aligos Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 06, 2023-Piper Sandler$3.00$1.22146.91%-68.59%
Jan 06, 2023-Jefferies$3.00$0.99203.03%-68.59%
Row per page
Go to

The latest Aligos Therapeutics stock forecast, released on Jan 06, 2023 by Piper Sandler company, set a price target of $3.00, which represents a 146.91% increase from the stock price at the time of the forecast ($1.22), and a -68.59% decrease from ALGS last price ($9.55).

Aligos Therapeutics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$9.55$9.55$9.55
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Aligos Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aligos Therapeutics's last price of $9.55. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 20, 2024H.C. WainwrightBuyBuyHold
Sep 12, 2024Piper SandlerOverweightOverweightHold
Aug 19, 2024H.C. Wainwright-BuyInitialise
Jul 19, 2024Piper SandlerOverweightOverweightHold
May 17, 2024Piper SandlerOverweightOverweightHold
Jan 06, 2023Barclays-Equal-WeightDowngrade
Jan 06, 2023Wedbush-NeutralDowngrade
Jan 06, 2023Raymond James-OutperformDowngrade
Jan 06, 2023J.P. Morgan-NeutralDowngrade
Jan 06, 2023Piper SandlerOverweightNeutralDowngrade
Row per page
Go to

Aligos Therapeutics's last stock rating was published by H.C. Wainwright on Sep 20, 2024. The company gave ALGS a "Buy" rating, the same as its previous rate.

Aligos Therapeutics Financial Forecast


Aligos Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Dec 22Sep 22Mar 22Mar 21
Revenue---------$3.54M$4.11M$2.57M$910.00K
Avg Forecast$333.33K$333.33K$333.33K$333.33K$333.33K$333.33K$1.06M$1.60M$2.50M$2.15M$750.00K$2.18M$1.07M
High Forecast$333.33K$333.33K$333.33K$333.33K$333.33K$333.33K$1.06M$1.60M$2.50M$2.15M$750.00K$2.62M$1.29M
Low Forecast$333.33K$333.33K$333.33K$333.33K$333.33K$333.33K$1.06M$1.60M$2.50M$2.15M$750.00K$1.75M$857.42K
# Analysts1111121111799
Surprise %---------1.65%5.47%1.18%0.85%

Aligos Therapeutics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $2.50M, with a low forecast of $2.50M, and a high forecast of $2.50M. ALGS's average Quarter revenue forecast represents a -29.32% decrease compared to the company's last Quarter revenue of $3.54M (Dec 22).

Aligos Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Dec 22Sep 22Mar 22Mar 21
# Analysts1111121111799
EBITDA--------$-19.07M$-22.68M$-18.04M$-34.57M$-26.76M
Avg Forecast$-66.67K$-66.67K$-66.67K$-66.67K$-66.67K$-66.67K$-212.20K$-320.00K$-500.00K$-430.00K$-150.00K$-29.30M$-31.51M
High Forecast$-66.67K$-66.67K$-66.67K$-66.67K$-66.67K$-66.67K$-212.20K$-320.00K$-500.00K$-430.00K$-150.00K$-23.44M$-25.21M
Low Forecast$-66.67K$-66.67K$-66.67K$-66.67K$-66.67K$-66.67K$-212.20K$-320.00K$-500.00K$-430.00K$-150.00K$-35.15M$-37.82M
Surprise %--------38.14%52.75%120.28%1.18%0.85%

undefined analysts predict ALGS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aligos Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aligos Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Dec 22Sep 22Mar 22Mar 21
# Analysts1111121111799
Net Income--------$-18.04M$-21.89M$-18.62M$-35.62M$-27.67M
Avg Forecast$-20.55M$-20.09M$-19.13M$-18.80M$-9.34M$-13.51M$-25.06M$-43.86M$-74.41M$-78.32M$-90.86M$-30.25M$-32.59M
High Forecast$-20.55M$-20.09M$-19.13M$-18.80M$-9.34M$2.83M$-25.06M$-17.87M$-74.41M$-78.32M$-90.86M$-24.20M$-26.08M
Low Forecast$-20.55M$-20.09M$-19.13M$-18.80M$-9.34M$-27.66M$-25.06M$-69.85M$-74.41M$-78.32M$-90.86M$-36.30M$-39.11M
Surprise %--------0.24%0.28%0.20%1.18%0.85%

Aligos Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALGS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aligos Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Dec 22Sep 22Mar 22Mar 21
# Analysts1111121111799
SG&A--------$6.44M$7.12M$5.26M$6.45M$5.78M
Avg Forecast$811.48K$811.48K$811.48K$811.48K$811.48K$811.48K$2.58M$3.90M$6.09M$5.23M$1.83M$5.32M$2.61M
High Forecast$811.48K$811.48K$811.48K$811.48K$811.48K$811.48K$2.58M$3.90M$6.09M$5.23M$1.83M$6.38M$3.13M
Low Forecast$811.48K$811.48K$811.48K$811.48K$811.48K$811.48K$2.58M$3.90M$6.09M$5.23M$1.83M$4.25M$2.09M
Surprise %--------1.06%1.36%2.88%1.21%2.22%

Aligos Therapeutics's average Quarter SG&A projection for Dec 23 is $3.90M, based on 1 Wall Street analysts, with a range of $3.90M to $3.90M. The forecast indicates a -39.54% fall compared to ALGS last annual SG&A of $6.44M (Sep 23).

Aligos Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Sep 23Dec 22Sep 22Mar 22Mar 21
# Analysts1111121111799
EPS--------$-0.41$-0.51$-0.44$-0.84$-0.74
Avg Forecast$-3.28$-3.21$-3.05$-3.00$-1.49$-2.16$-4.00$-7.00$-11.88$-12.50$-14.50$-18.19$-22.50
High Forecast$-3.28$-3.21$-3.05$-3.00$-1.49$0.45$-4.00$-2.85$-11.88$-12.50$-14.50$-18.19$-22.50
Low Forecast$-3.28$-3.21$-3.05$-3.00$-1.49$-4.41$-4.00$-11.15$-11.88$-12.50$-14.50$-18.19$-22.50
Surprise %--------0.03%0.04%0.03%0.05%0.03%

According to undefined Wall Street analysts, Aligos Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALGS previous annual EPS of $NaN (undefined).

Aligos Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SPROSpero Therapeutics$1.18$10.00747.46%Buy
CTMXCytomX Therapeutics$1.05$5.77449.52%Buy
NUVBNuvation Bio$2.30$6.75193.48%Buy
TILInstil Bio$28.78$78.25171.89%Hold
NXTCNextCure$1.33$3.00125.56%Buy
ASMBAssembly Biosciences$16.89$35.50110.18%Buy
ACHLAchilles Therapeutics$1.02$2.0096.08%Buy
ALGSAligos Therapeutics$9.55$3.00-68.59%Hold

ALGS Forecast FAQ


No, according to 13 Wall Street analysts, Aligos Therapeutics (ALGS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 30.77% of ALGS's total ratings.

Aligos Therapeutics (ALGS) average price target is $3 with a range of $3 to $3, implying a -68.59% from its last price of $9.55. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ALGS stock, the company can go down by -68.59% (from the last price of $9.55 to the average price target of $3), down by -68.59% based on the highest stock price target, and down by -68.59% based on the lowest stock price target.

ALGS's average twelve months analyst stock price target of $3 does not support the claim that Aligos Therapeutics can reach $14 in the near future.

Aligos Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.73M (high $1.73M, low $1.73M), average EBITDA is $-346K (high $-346K, low $-346K), average net income is $-47.913M (high $-31.571M, low $-62.055M), average SG&A $4.21M (high $4.21M, low $4.21M), and average EPS is $-7.647 (high $-5.039, low $-9.904). ALGS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.33M (high $1.33M, low $1.33M), average EBITDA is $-267K (high $-267K, low $-267K), average net income is $-78.575M (high $-78.575M, low $-78.575M), average SG&A $3.25M (high $3.25M, low $3.25M), and average EPS is $-12.54 (high $-12.54, low $-12.54).

Based on Aligos Therapeutics's last annual report (Dec 2022), the company's revenue was $13.91M, beating the average analysts forecast of $5.08M by 173.57%. Apple's EBITDA was $-97.58M, beating the average prediction of $-29.875M by 226.62%. The company's net income was $-96.046M, missing the average estimation of $-199M by -51.84%. Apple's SG&A was $26.41M, beating the average forecast of $12.38M by 113.40%. Lastly, the company's EPS was $-2.25, missing the average prediction of $-45.188 by -95.02%. In terms of the last quarterly report (Dec 2022), Aligos Therapeutics's revenue was $3.54M, beating the average analysts' forecast of $2.15M by 64.51%. The company's EBITDA was $-22.682M, beating the average prediction of $-430K by 5174.90%. Aligos Therapeutics's net income was $-21.886M, missing the average estimation of $-78.324M by -72.06%. The company's SG&A was $7.12M, beating the average forecast of $5.23M by 36.01%. Lastly, the company's EPS was $-0.51, missing the average prediction of $-12.5 by -95.92%